Aclaris Therapeutics

Historical price data

Aclaris Therapeutics is a publicly traded biotech company dedicated to addressing unmet needs in immuno-inflammatory and dermatological conditions through targeted kinase inhibition. The company's core strategy revolves around its internal KINect® discovery platform, which has generated a pipeline of investigational compounds. Key assets include zunsemetinib (ATI-450), an oral MK2 inhibitor in Phase 2b trials for rheumatoid arthritis and psoriatic arthritis, and sofpironium bromide, a topical anticholinergic approved in Japan for primary axillary hyperhidrosis. Aclaris is navigating a strategic shift, having discontinued its earlier commercial dermatology efforts to concentrate resources on its clinical-stage pipeline.

The KINect® drug discovery platform is an integrated structure- and property-based design engine used to identify novel small molecule inhibitors of kinases for immuno-inflammatory diseases.

35 drugs in pipeline, 6 in Phase 3

Faces competition from large pharma companies with dominant biologics and JAK inhibitors in rheumatology (e.g., AbbVie, Pfizer, Lilly) and dermatology (e.g., Incyte, Pfizer). Differentiation relies on demonstrating superior safety or efficacy through novel kinase targets like MK2 and ITK.